Literature DB >> 25395220

Uncovering methods for the prevention of protein aggregation and improvement of product quality in a transient expression system.

Bram Estes1, Yueh-Rong Hsu, Lei-Ting Tam, Jackie Sheng, Jennitte Stevens, Raj Haldankar.   

Abstract

Mammalian expression systems are used routinely for the production of recombinant proteins as therapeutic molecules as well as research tools. Transient expression has become increasingly popular in recent years due to its rapid timeline and improvements in expression level. While improvements to transient expression systems have focused mainly on the level of protein expression, the aspect of protein quality has received little attention. The removal of undesirable products, such as aggregation, depends primarily on purification, requiring additional cumbersome steps, which can lead to a lower product yield and longer timelines. In this study, we show that reducing the level of transcription by transfecting at a lower gene dose improves the quality of secreted molecules prone to aggregation. For gene dosing to have this effect, it is critical for the carrier DNA to be an empty vector containing the same elements as the gene containing plasmid. This approach can be used in combination with a temperature shift to hypothermic conditions during production to enhance the effect. The observed improvements not only minimized aggregation levels, but also generated products with overall superior quality, including more homogeneous signal peptide cleavage and N-linked glycosylation profiles. These techniques have produced a similar improvement in product quality with a variety of other molecules, suggesting that this may be a general approach to enhance product quality from transient expression systems.
© 2014 The Authors. Published by Wiley Periodicals, Inc. on behalf of American Institute of Chemical Engineers.

Entities:  

Keywords:  293-EBNA1; aggregation; gene dosage; mild hypothermia; transient expression

Mesh:

Substances:

Year:  2014        PMID: 25395220     DOI: 10.1002/btpr.2021

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  9 in total

1.  Post-translationally modified muscle-specific ubiquitin ligases as circulating biomarkers in experimental cancer cachexia.

Authors:  Roberto Mota; Jessica E Rodríguez; Andrea Bonetto; Thomas M O'Connell; Scott A Asher; Traci L Parry; Pamela Lockyer; Christopher R McCudden; Marion E Couch; Monte S Willis
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

2.  A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair.

Authors:  Monica Florio; Kannan Gunasekaran; Marina Stolina; Xiaodong Li; Ling Liu; Barbara Tipton; Hossein Salimi-Moosavi; Franklin J Asuncion; Chaoyang Li; Banghua Sun; Hong Lin Tan; Li Zhang; Chun-Ya Han; Ryan Case; Amy N Duguay; Mario Grisanti; Jennitte Stevens; James K Pretorius; Efrain Pacheco; Heidi Jones; Qing Chen; Brian D Soriano; Jie Wen; Brenda Heron; Frederick W Jacobsen; Emil Brisan; William G Richards; Hua Zhu Ke; Michael S Ominsky
Journal:  Nat Commun       Date:  2016-05-27       Impact factor: 14.919

3.  Impact of different promoters, promoter mutation, and an enhancer on recombinant protein expression in CHO cells.

Authors:  Wen Wang; Yan-Long Jia; Yi-Chun Li; Chang-Qin Jing; Xiao Guo; Xue-Fang Shang; Chun-Peng Zhao; Tian-Yun Wang
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

Review 4.  Nanoscale integration of single cell biologics discovery processes using optofluidic manipulation and monitoring.

Authors:  Marsela Jorgolli; Tanner Nevill; Aaron Winters; Irwin Chen; Su Chong; Fen-Fen Lin; Marissa Mock; Ching Chen; Kim Le; Christopher Tan; Philip Jess; Han Xu; Agi Hamburger; Jennitte Stevens; Trent Munro; Ming Wu; Philip Tagari; Les P Miranda
Journal:  Biotechnol Bioeng       Date:  2019-06-24       Impact factor: 4.530

5.  Therapeutic Fc fusion protein misfolding: A three-phasic cultivation experimental design.

Authors:  Atefeh Ghorbani Aghdam; Saeed Moradhaseli; Farnoush Jafari; Paria Motahari; Sepideh Samavat; Rasoul Mahboudi; Shayan Maleknia
Journal:  PLoS One       Date:  2019-01-16       Impact factor: 3.240

6.  Impact of SARS-CoV-2 RBD Mutations on the Production of a Recombinant RBD Fusion Protein in Mammalian Cells.

Authors:  Guillaume Gerez; Jerome Martinez; Christophe Steinbrugger; Sandra Bouanich; Johanna Dimino; Corine Piegay; Maxime Combe; Franck Berthier; Soizic Daniel
Journal:  Biomolecules       Date:  2022-08-24

7.  A protein chimera strategy supports production of a model "difficult-to-express" recombinant target.

Authors:  Hirra Hussain; David I Fisher; Robert G Roth; W Mark Abbott; Manuel Alejandro Carballo-Amador; Jim Warwicker; Alan J Dickson
Journal:  FEBS Lett       Date:  2018-07-03       Impact factor: 4.124

8.  Production of high-quality SARS-CoV-2 antigens: Impact of bioprocess and storage on glycosylation, biophysical attributes, and ELISA serologic tests performance.

Authors:  Rute Castro; Lígia S Nobre; Rute P Eleutério; Mónica Thomaz; António Pires; Sandra M Monteiro; Sónia Mendes; Ricardo A Gomes; João J Clemente; Marcos F Q Sousa; Filipe Pinto; Ana C Silva; Micael C Freitas; Ana R Lemos; Onome Akpogheneta; Lindsay Kosack; Marie-Louise Bergman; Nadia Duarte; Paula Matoso; Júlia Costa; Tiago M Bandeiras; Patricia Gomes-Alves; Carlos P Gonçalves; Jocelyne Demengeot; Paula M Alves
Journal:  Biotechnol Bioeng       Date:  2021-03-27       Impact factor: 4.395

9.  The CAG promoter maintains high-level transgene expression in HEK293 cells.

Authors:  Yuanyuan Dou; Yan Lin; Tian-Yun Wang; Xiao-Yin Wang; Yan-Long Jia; Chun-Peng Zhao
Journal:  FEBS Open Bio       Date:  2020-12-03       Impact factor: 2.792

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.